Barriers to receipt of novel oral oncolytics: A single-institution quality improvement investigation.

Ann Andee WangChristopher TapiaYasin BhanjiChristopher CampbellDaniel LarsenDerick GrossSeema GanatraMelad QodsiClaudia TellezShikha Jain

Published in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2019)

Insurance has a significant effect on the time-to-receipt of newly prescribed novel oral oncolytics. Pharmacy transfers and applying for cost assistance are also associated with longer wait times for patients. Our retrospective analysis identifies areas of improvement for future interventions to reduce wait times for patients receiving novel oral oncolytics.

Keyphrases

quality improvement
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
physical activity
peritoneal dialysis
genome wide
healthcare
health insurance
patient reported outcomes
long term care
affordable care act